Clinics and Research in Hepatology and Gastroenterology
Case reportLymph node metastasis diagnosed by EUS-FNA in four cases with hepatocellular carcinoma☆
Introduction
Lymph node (LN) metastasis is rarely recognized in patients with hepatocellular carcinoma (HCC) and Liver Cancer Study Group of Japan reported a prevalence of LN metastasis only in 2.2% [1]∼7.4% [2] of resected cases of HCC. In such cases, accurate diagnosis of nodal lesion was difficult only with clinical images and serum tumor markers. Although usefulness of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was reported for the diagnosis of lymphadenopathy in the last few years [3], [4], there is no report in cases with HCC. HCC is one of the most vascular-rich human tumors and is often affected by repetitive interventional therapies at the stage with metastasis. The purpose of this study is to evaluate the efficacy and safety of EUS-FNA of LN metastasis in patients with HCC and to determine the characteristic CT image of nodal metastasis of HCC in correlation with histology.
Section snippets
Materials and methods
In Shizuoka Cancer Center, 17 cases with lymphadenopathy were finally diagnosed using EUS-FNA from April 2003 to December 2009 and all revealed to be malignant. Four out of these 17 (23.5%) cases were accompanied with HCC (Table 1). In these cases, before EUS-FNA, dynamic compute tomography (CT) was performed for the assessment of possible access route to the target LN, and CT value was analyzed to clarify characteristics of metastatic LN in cases with HCC.
Case presentation
Clinicopathological findings of four patients were summarized in Table 1. In these cases, three cases were positive hepatitis-C antibody. In three cases, metastasis was recognized at the posterior region of the pancreatic head. One case (Case 1) had a history of interventional therapies for primary cancer. Before EUS-FNA, nodal lymphoma and metastasis from unknown primary tumor had been also suspected. In EUS-FNA, target LN was well visualized and enough amount of sample was obtained even with
Discussion
For the important treatment choice, accurate diagnosis is necessary. In current four cases, two cases changed their treatments and the remaining two cases could stay away from adding unbeneficial treatment by a technically easy method, EUS-FNA. In the previous reports on EUS-FNA in the cases with lymphadenopathy, the methodology was quite similar except for the caliber size of the needles. For instance, a 19-gauge needle was used for the cases of malignant lymphoma, for which diagnosis a large
Conflict of interest statement
No conflict of interest.
Acknowledgements
Authors are grateful to Ms. Asami Nakagawa and Ms. Satomi Koizumi for their faithful nursing and managements on the patients.
References (11)
Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment
Ann Surg
(1990)- et al.
Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma
World J Surg
(2010) - et al.
Usefulness of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for undiagnosed intra-abdominal lymphadenopathy
J Gastroenterol
(2009) - et al.
Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of unknown origin
Endoscopy
(2006) - et al.
Endoscopic ultrasonography-guided fine-needle cytodiagnosis of mediastinal metastases from renal cell cancer
Endoscopy
(2000)
Cited by (10)
Percutaneous Microwave Ablation of Hepatocellular Carcinoma Metastatic to a Mesocolic Lymph Node
2017, Journal of Vascular and Interventional RadiologyEndoscopic ultrasound guided hepatic interventions
2021, Digestive EndoscopyDiagnostic yield of endoscopic ultrasound-guided biopsy of focal liver lesions
2019, Medicine and Pharmacy ReportsImpact of endoscopic ultrasound-guided fine-needle aspiration in prospective liver transplant recipients with hepatocellular carcinoma and lymphadenopathy
2016, Indian Journal of GastroenterologyEndoscopic ultrasound-guided liver biopsy
2015, Endoscopic Ultrasound
- ☆
IRB Approval: Institutional Review Board of Shizuoka Cancer Center approved this study (Institutional code no.: 22-J48-22-1-3).